BioPorto

Company Description

---

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is a significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early.

Headquarters

---

Tuborg Havnevej 15, 2900 Hellerup – Denmark

Shares outstanding

---

334,693,005

IPO

---

Jan. 1, 2000

Stock exchange(s)

---

Nasdaq Copenhagen